Monitor enrollment updates and any early efficacy signals from NOV-ERA; the primary endpoint readout at Week 24 is the next major catalyst. The €7M milestone is small relative to typical biotech financing needs, so the stock move will depend on investor perception of trial design and market opportunity for a first-in-class anti-fibrotic in FSCD.
Price Chart
Executive Summary
Agomab Therapeutics dosed the first patient in its Phase 2b NOV-ERA trial of ontunisertib for Fibrostenosing Crohn's disease, triggering a €7 million milestone payment to former Origo Biopharma shareholders. The study enrolls ~320 patients across three dose levels vs placebo, with primary endpoint at Week 24. This is a positive clinical milestone for a high-unmet-need indication with no approved anti-fibrotic therapy, but the stock impact is tempered by the early-stage nature of the data and the small absolute milestone amount.
Key Financial Metrics
Key Facts
- First patient dosed in global Phase 2b NOV-ERA trial of ontunisertib (AGMB-129) for symptomatic Fibrostenosing Crohn's disease (FSCD).
- Trial is randomized, double-blind, placebo-controlled, dose-ranging, enrolling ~320 patients across 3 dose levels (400 mg, 200 mg, 100 mg BID) and placebo.
- Primary endpoint: proportion of patients achieving endoscopic passability of ileal index stricture at Week 24.
- Study initiation triggers a €7 million milestone payment to former Origo Biopharma shareholders under the 2021 acquisition agreement.
- Ontunisertib has U.S. FDA Fast Track Designation.
- Positive Phase 2a STENOVA results and long-term safety/tolerability OLE data support the Phase 2b design.
Financial Impact
€7 million milestone payment triggered; up to €20 million total potential development/regulatory milestones from the 2021 Origo acquisition, of which €10 million has become payable to date (including €3 million paid in 2025).
Risk Factors
- Phase 2b trial may fail to meet primary endpoint; no approved anti-fibrotic therapy exists for FSCD, so regulatory path is uncertain.
- Competition from other fibrosis-targeting programs in Crohn's disease.
- Company is clinical-stage with no approved products; financing risk if milestones or equity raises are needed.
- Small absolute milestone payment suggests limited near-term financial impact.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3380153 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Insider Buy | $9.26 | awaiting T+5 | — | $8.57 (−7.45%) |
Oct 13, 2026 13d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 13, 2026 13d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.57 (−1.38%) |
Oct 1, 2026 25d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Oct 1, 2026 25d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.57 (−0.92%) |
Sep 14, 2026 6w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 14, 2026 6w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.57 (−29.52%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $8.57 (−30.21%) |
Aug 10, 2026 11w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $8.57 (−42.29%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $8.57 (−32.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers